Biomedical Sensor Market Global Report 2026

The biomedical sensor market size has grown rapidly in recent years. It will grow from $13.85 billion in 2025 to $15.27 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to the increasing burden of chronic illnesses, growing demand for continuous monitoring of patients, rising adoption of wearable healthcare technologies, increasing need for early identification of diseases, and growing demand for non-invasive diagnostic solutions.

The biomedical sensor market size is expected to see strong growth in the next few years. It will grow to $22.2 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for healthcare monitoring within home environments, rising adoption of remote patient monitoring solutions, growing need for individualized health measurements, expanding application of biomedical sensors in preventive healthcare, and increasing demand for real-time monitoring of physiological parameters. Major trends in the forecast period include growing adoption of non-invasive biomedical sensing technologies, rising demand for continuous monitoring of physiological indicators, increasing use of wearable biomedical sensors for individual health tracking, growing demand for real-time disease identification and diagnosis, and rising preference for compact biomedical sensing devices that are portable and convenient to use.

The rising prevalence of chronic disease is expected to propel the growth of the biomedical sensor market going forward. Chronic diseases are long-term medical conditions, including diabetes, cardiovascular disease, and cancer, that persist over an extended period and require continuous medical management. The increasing prevalence of chronic diseases is largely attributed to aging populations, as older individuals are considerably more susceptible to developing multiple long-term conditions, creating greater pressure on healthcare systems to provide continuous and proactive care. The growing burden of chronic conditions is increasing demand for biomedical sensors that continuously monitor and transmit patient health data, enabling real-time monitoring and timely clinical interventions. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. Therefore, the rising prevalence of chronic disease is driving the growth of the biomedical sensor market.

Key companies operating in the biomedical sensor market are focusing on developing advanced solutions, such as over-the-counter glucose biosensors, to expand access to continuous health monitoring, improve user convenience, and support proactive wellness management. An over-the-counter glucose biosensor is a wearable sensing device that continuously measures glucose levels without requiring a prescription, enabling users to monitor glucose trends in real time. For example, in August 2024, DexCom Inc., a US-based medical device company, launched Stelo, the first over-the-counter glucose biosensor available in the United States. It is designed for adults aged 18 years and older who are not using insulin. Stelo is an over-the-counter glucose biosensor that enables continuous glucose monitoring through a smartphone application, providing real-time glucose insights, personalized recommendations, meal logging, and activity tracking to support informed metabolic health management.

In June 2026, Danaher Corporation, a US-based healthcare company, acquired Masimo Corporation for $9.9 billion. Through this acquisition, Danaher aims to enhance its diagnostics portfolio by broadening its patient monitoring capabilities, incorporating Masimo’s advanced sensor and AI-enabled monitoring technologies, and supporting innovation and growth within acute care diagnostics. Masimo Corporation is a US-based medical technology company that develops and manufactures a broad range of biomedical sensors for noninvasive patient monitoring.

Major companies operating in the biomedical sensor market are Johnson & Johnson, Roche Holding AG, Abbott Laboratories, Medtronic plc, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Texas Instruments Incorporated, Analog Devices Inc., Becton Dickinson and Company, Honeywell International Inc., STMicroelectronics N.V., Terumo Corporation, ON Semiconductor Corporation, OMRON Corporation, DexCom Inc., Amphenol Corporation, OSI Systems Inc., ICU Medical Inc., Nihon Kohden Corporation, Merit Medical Systems Inc., iRhythm Technologies Inc., Senseonics Holdings Inc., Nonin Medical Inc.

North America was the dominating region in the biomedical sensor market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the biomedical sensor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biomedical sensor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.